Overview

Apixaban in Patients With Sickle Cell Disease

Status:
Terminated
Trial end date:
2017-09-03
Target enrollment:
Participant gender:
Summary
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs. This study attempts to critically avoid admissions by reducing daily pain scores and pain crisis as an outpatient by use of a novel oral anticoagulant.
Phase:
Phase 3
Details
Lead Sponsor:
Nirmish Shah
Collaborator:
Bristol-Myers Squibb
Treatments:
Apixaban